Simultaneous Bilateral THA Is as Safe as Staged Procedures

    Many joint replacement surgeons avoid simultaneous bilateral total hip arthroplasty (THA) for their patients with bilateral end-stage hip osteoarthritis due to concerns about higher complications rates reported in previous studies.

    A new study from Mayo Clinic, Rochester, Minnesota, indicates these concerns may be unfounded: Simultaneous bilateral THA was not associated with a higher risk of postoperative 30- and 90-day mortality, infection, dislocation, or wound complications compared with staged bilateral THA. Only the risk of deep vein thrombosis was higher in the simultaneous than in the staged bilateral THA group.

    There were a few demographic differences in the group: Patients in the simultaneous bilateral THA group were younger and had a lower BMI, plus more patients in this group were male, suggesting that patient selection is an important factor in a successful procedure.

    Implant survival was not an issue: The overall 2-, 5-, 10-, and 15-year survival of all bilateral THAs was 99%, 97%, 90%, and 81%, respectively, with no difference in the overall 15-year survival between the staged and simultaneous THA groups.

    We sat down with Michael J. Taunton, MD, one of the study authors, to discuss the results in more detail. Click the image above to hear his comments.

    Producer and Director: Michael Bugera; Post Production: Charles Maynard


    Houdek MT, Wagner ER, Wyles CC, Sierra RJ, Trousdale RT, Taunton MJ. Simultaneous Bilateral vs. Staged Bilateral Total Hip Arthroplasty: A Survival Study (Paper 163). Presented at the Mid-America Orthopaedic Association Annual Meeting, April 22-25, 2015, Hilton Head Island, South Carolina.